8-K 1 a2090682z8-k.htm 8-K
QuickLinks -- Click here to rapidly navigate through this document

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported) September 30, 2002

NeoPharm, Inc.
(Exact name of registrant as specified in its charter)


Delaware
 
33-90516
 
51-0327886
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

150 Field Drive, Suite 195, Lake Forest, IL 60045
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code (847) 295-8678

(Former name or former address, if changed since last report)


Item 5.    Other Events and Regulation FD Disclosure

        On September 20, 2002, the Issuer's Board of Directors adopted a resolution to extend the Company's Common Stock Repurchase Program (the "Repurchase Program") for an additional twelve month period. Under the terms of the Repurchase Program, the Issuer is authorized to purchase up to 1,000,000 shares over the next twelve months. Any purchases under the Repurchase Program may be made, from time to time, in the open market, through block trades or otherwise and, depending on market conditions and other factors, may be commenced or suspended at any time or from time to time without prior notice. Repurchased shares may be used for the Issuer's employee benefit plans, subsequent acquisitions or other general corporate purposes.

Regulation FD Disclosure

        On September 30, 2002, the Issuer issued a press release relating to the authorization by the Issuer's Board of Directors of a Stock Repurchase Program. A copy of the press release is attached as Exhibit 99.1.


Item 7.    Financial Statements, Pro Forma Financials and Exhibits

(c)
Exhibits
Exhibit Number
   Description
    

99.1
 
Press Release dated September 30, 2002.
 
 

2


SIGNATURE PAGE

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 
 
NEOPHARM INC.

 
 
 
 

Date: October 4, 2002
 
By:
/s/  LAWRENCE A. KENYON      
Lawrence A. Kenyon,
 Chief Financial Officer
(Principal Accounting Officer and
Principal Financial Officer)

 
 
 
 

3



QuickLinks

SIGNATURE PAGE